Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-CEA antibody variable domains fused with a scFv from an anti-DR5 antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can induce targeted apoptosis by activation of the death receptor. It is designed for the research of Breast cancer; Ovary cancer; Colon cancer; Lung cancer therapy.